Research Triangle Park, NC; June 15, 2015 – Spyryx Biosciences, Inc., a privately-held biopharmaceutical company developing novel therapeutics for respiratory diseases, including cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD), announced today that it has appointed Timothy Crowder, PhD as its VP, Technical Operations. In this role, Dr. Crowder will be responsible for inhalation delivery technologies for Spyryx’ pulmonary therapeutics and for developing and executing manufacturing and supply chain strategies for these products. He will report to John Taylor, Spyryx’ President and CEO, and is being tasked with providing leadership and operational oversight to all aspects of clinical and commercial product supply.
Dr. Crowder joins Spyryx from GlaxoSmithKline, where he was most recently Director of Advanced Manufacturing Technology, leading innovation in the areas of aerosol release testing, technology enhanced manufacturing strategies, electronic inhaler technology and particle engineering technology. Earlier in his GSK career, he contributed to late-stage development of GSK’s current asthma and COPD products. Prior to GSK, Dr. Crowder was a co-founder of Oriel Therapeutics, an inhaler technology company built around device designs he developed during his graduate research. Oriel was subsequently acquired by Sandoz Pharmaceuticals in 2010. Dr. Crowder earned his PhD in Biomedical Engineering from the University of North Carolina-Chapel Hill and has degrees in Physics from North Carolina State University and Davidson College. He is an inventor on 10 issued patents on inhalers and powder filling systems and has 25 publications, book chapters and international presentations in aerosol drug delivery, inhaler design, powder filling, powder flow, formulation and characterization.
“Timm has an accomplished track record in inhalation and we are pleased to have attracted an individual of his caliber to manage our technical operations and manufacturing functions,” stated Mr. Taylor. “Our recent funding has allowed us to assemble the team and resources to rapidly advance our science and product development. With the addition of a Chief Medical Officer, who we are still seeking, our team will be fully staffed.”
“Spyryx is working on important new approaches to addressing devastating lung diseases, such as CF, and I am excited to have the opportunity to support the Company’s efforts to deliver these novel therapies to patients who have few effective treatment options,” commented Dr. Crowder.
About Spyryx Biosciences
Spyryx Biosciences is a biopharmaceutical company developing inhaled therapeutics to address severe obstructive lung diseases via modulation of a novel biological mechanism. The Company’s products have been created to mimic the ENaC inhibitory effect of SPLUNC1, a lung protein that regulates airway fluid volume. Founded in 2013, Spyryx’ lead program is in pre-clinical development for cystic fibrosis. Further information regarding Spyryx Biosciences is available at www.spyryxbio.com.
Company Contact: John Taylor